The stock price of Nextcure Inc (NASDAQ: NXTC) has jumped by 4.73 compared to previous close of 0.47. Despite this, the company has seen a fall of -0.18% in its stock price over the last five trading days. globenewswire.com reported 2025-05-29 that BELTSVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class and best-in-class therapies to treat cancer, together with LigaChem Biosciences, Inc. (LigaChemBio) announced that a trial in progress poster from the Phase 1 study evaluating LNCB74, a B7-H4 targeted antibody-drug conjugate (ADC), will be presented at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
Is It Worth Investing in Nextcure Inc (NASDAQ: NXTC) Right Now?
The 36-month beta value for NXTC is at 1.08. Analysts have varying views on the stock, with 0 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NXTC is 21.44M, and currently, shorts hold a 1.48% of that float. The average trading volume for NXTC on June 06, 2025 was 166.81K shares.
NXTC’s Market Performance
NXTC stock saw an increase of -0.18% in the past week, with a monthly gain of 12.61% and a quarterly increase of -30.50%. The volatility ratio for the week is 3.13%, and the volatility levels for the last 30 days are 5.47% for Nextcure Inc (NXTC). The simple moving average for the past 20 days is 6.01% for NXTC’s stock, with a -46.71% simple moving average for the past 200 days.
Analysts’ Opinion of NXTC
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see NXTC reach a price target of $16. The rating they have provided for NXTC stocks is “Buy” according to the report published on March 01st, 2022.
Truist gave a rating of “Buy” to NXTC, setting the target price at $19 in the report published on March 05th of the previous year.
NXTC Trading at 14.66% from the 50-Day Moving Average
After a stumble in the market that brought NXTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.77% of loss for the given period.
Stock Fundamentals for NXTC
The total capital return value is set at -0.86. Equity return is now at value -63.94, with -54.33 for asset returns.
Based on Nextcure Inc (NXTC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -8.38.
Currently, EBITDA for the company is -52.79 million with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.26.
Conclusion
In conclusion, Nextcure Inc (NXTC) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
